NL-OMON20855招募中不适用
Rituximab in Primary Central Nervous system Lymphoma.A randomized HOVON / ALLG intergroup study.
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedP.O. box 52013008 AE RotterdamTel: +31 10 7041560Fax: +31 10 7041028e-mail: hdc@erasmusmc.nl0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with a histologically confirmed diagnosis of CD20 positive DLBCL based upon a representative histology specimen of brain biopsy according to the WHO classification;
排除标准
- •1. Evidence of systemic lymphoma;
- •2. History of intolerance of exogenous protein administration;
研究者
相似试验
进行中（未招募）
3 期
Rituximab in Primary Central Nervous system Lymphoma.A randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup studyprimary central nervous system (CNS) lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12610000908033HOVO45
进行中（未招募）
不适用
Rituximab in Primary Central Nervous system Lymphoma.A randomized HOVON / ALLG intergroup studyEUCTR2009-014722-42-NLHOVON Foundation200
已完成
3 期
Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON / ALLG intergroup studyPrimary Central Nervous system Lymphoma10025320NL-OMON43562HOVO130
尚未招募
不适用
Rituximab for anti-NMDAR encephalitisJPRN-UMIN000026293Tokushima University Hospital2
已完成
1 期
A Pilot Trial of Rituxan in Refractory Myasthenia GravisRefractory Myasthenia GravisNCT00619671University of Vermont10